Amgen, UCB Get EU Approval for Evenity in Osteoporosis
December 12 2019 - 6:49AM
Dow Jones News
By Colin Kellaher
Amgen Inc. (AMGN) and UCB S.A. (UCB.BT) Thursday said the
European Commission granted marketing authorization for Evenity for
the treatment of severe osteoporosis in postmenopausal women at
high risk of fracture, marking the first approval of a new
osteoporosis medicine in the European Union since 2010.
The companies said they plan the first launches of Evenity,
which increases bone formation and reduces bone loss, in the
European Economic Area in the first half of 2020.
Amgen, a Thousand Oaks, Calif., biotechnology company, and UCB,
a Brussels biopharmaceutical company, are co-developing Evenity
under a collaboration and license agreement they inked in 2004.
The European Medicines Agency's Committee for Medicinal Products
for Human Use in October recommended approval of the drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 12, 2019 06:34 ET (11:34 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
